{
  "protocolSection": {
    "identificationModule": null,
    "descriptionModule": null,
    "conditionsModule": null,
    "designModule": null,
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Sarilumab group",
          "type": "EXPERIMENTAL",
          "description": "Patients received usual care plus sarilumab 400 mg intravenously on day 1, with an optional additional 400 mg dose on day 3 if oxygen requirement had not decreased by more than 50%",
          "interventionNames": [
            "Drug: Sarilumab",
            "Other: Usual care"
          ]
        },
        {
          "label": "Usual care group",
          "type": "NO_INTERVENTION",
          "description": "Patients received usual care alone (antibiotic agents, antiviral agents, corticosteroids, vasopressor support, anticoagulants) provided at the discretion of the clinicians",
          "interventionNames": [
            "Other: Usual care"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "Sarilumab",
          "description": "400 mg administered intravenously on day 1, with possible additional 400 mg dose on day 3 based on clinical response (if oxygen requirement had not decreased by more than 50%)",
          "armGroupLabels": [
            "Sarilumab group"
          ]
        },
        {
          "type": "OTHER",
          "name": "Usual care",
          "description": "Standard care including antibiotic agents, antiviral agents, corticosteroids, vasopressor support, and anticoagulants as determined by treating physicians",
          "armGroupLabels": [
            "Sarilumab group",
            "Usual care group"
          ]
        }
      ]
    },
    "outcomesModule": null,
    "eligibilityModule": null
  }
}